Last reviewed 2026-04-19 · How we verify

IV 14C-labeled PF-06700841

Pfizer · Phase 1 active Small molecule

IV 14C-labeled PF-06700841 is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development.

At a glance

Generic name	IV 14C-labeled PF-06700841
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IV 14C-labeled PF-06700841 CI brief — competitive landscape report
IV 14C-labeled PF-06700841 updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about IV 14C-labeled PF-06700841

What is IV 14C-labeled PF-06700841?

IV 14C-labeled PF-06700841 is a Small molecule drug developed by Pfizer.

Who makes IV 14C-labeled PF-06700841?

IV 14C-labeled PF-06700841 is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What development phase is IV 14C-labeled PF-06700841 in?

IV 14C-labeled PF-06700841 is in Phase 1.

Manufacturer: Pfizer — full pipeline
Compare: IV 14C-labeled PF-06700841 vs similar drugs
Pricing: IV 14C-labeled PF-06700841 cost, discount & access